Show simple item record

dc.contributor.authorThatcher, Nick
dc.contributor.authorHirsch, F
dc.contributor.authorLuft, A
dc.contributor.authorSzczesna, A
dc.contributor.authorCiuleanu, T
dc.contributor.authorDediu, M
dc.contributor.authorRamlau, R
dc.contributor.authorGaliulin, R
dc.contributor.authorBálint, B
dc.contributor.authorLosonczy, G
dc.contributor.authorKazarnowicz, A
dc.contributor.authorPark, K
dc.contributor.authorSchumann, C
dc.contributor.authorReck, M
dc.contributor.authorDepenbrock, H
dc.contributor.authorNanda, S
dc.contributor.authorKruljac-Letunic, A
dc.contributor.authorKurek, R
dc.contributor.authorPaz-Ares, L
dc.contributor.authorSocinski, M
dc.date.accessioned2015-07-22T14:05:02Zen
dc.date.available2015-07-22T14:05:02Zen
dc.date.issued2015-07en
dc.identifier.citationNecitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. 2015, 16 (7):763-74 Lancet Oncolen
dc.identifier.issn1474-5488en
dc.identifier.pmid26045340en
dc.identifier.doi10.1016/S1470-2045(15)00021-2en
dc.identifier.urihttp://hdl.handle.net/10541/560896en
dc.description.abstractNecitumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody. In this study, we aimed to compare treatment with necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone in patients with previously untreated stage IV squamous non-small-cell lung cancer.
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Oncologyen
dc.titleNecitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.en
dc.typeArticleen
dc.contributor.departmentThe Christie Hospital, Manchester, UK.en
dc.identifier.journalThe Lancet Oncologyen
html.description.abstractNecitumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody. In this study, we aimed to compare treatment with necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone in patients with previously untreated stage IV squamous non-small-cell lung cancer.


Files in this item

This item appears in the following Collection(s)

Show simple item record